Novo Nordisk A/S (NYSE:NVO) Receives Average Rating of “Hold” from Analysts

Novo Nordisk A/S (NYSE:NVO) has received a consensus recommendation of “Hold” from the twenty-one research firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $65.5625.

NVO has been the topic of a number of research analyst reports. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk beat second-quarter expectations, with adjusted sales rising 7% at constant exchange rates and adjusted operating profit increasing 11%. The company also raised its full-year sales and operating-profit outlook, citing continued demand for Wegovy and Ozempic, higher-dose injections and broader GLP-1 volume growth. Novo Nordisk’s Q2 profit beats forecasts, raises outlook
• Positive Sentiment: A Dutch court granted Novo a preliminary injunction against Ceban over an unapproved compounded semaglutide nasal spray, ordering the company to stop infringing activity and remove product listings. The ruling could help protect Novo’s semaglutide intellectual property and branded-product demand. Novo Nordisk wins Dutch court injunction
• Neutral Sentiment: CEO Mike Doustdar said Novo will prioritize faster internal research and smaller “bolt-on” acquisitions rather than transformational mergers. The strategy may conserve capital, but it also leaves investors looking for stronger pipeline evidence. Novo Nordisk not currently in a position to pursue large-scale M&A
• Negative Sentiment: Sales of the oral Wegovy pill were weaker than investors expected, raising concerns about the product’s launch trajectory and pricing economics. Analysts also noted that some quarterly strength came from rebate adjustments and other potentially temporary factors. Novo Nordisk’s raised forecast fails to change the debate over its obesity business
• Negative Sentiment: A setback in the late-stage CagriSema obesity-and-diabetes program weakened confidence in Novo’s next-generation pipeline. Investors are concerned that future products may not be sufficient to offset patent expirations, price reductions and intensifying competition from Lilly. Lilly climbs, Novo falls as obesity drug battle intensifies
• Negative Sentiment: Eli Lilly’s competing GLP-1 franchise delivered a 48% revenue increase to nearly $23 billion, substantially exceeding estimates. The result intensified concerns that Lilly is widening its commercial lead and capturing more of the fast-growing weight-loss market. Eli Lilly stock jumps as GLP-1 sales widen Novo lead

Novo Nordisk A/S Trading Up 0.4%

Shares of Novo Nordisk A/S stock opened at $44.48 on Thursday. The firm has a market capitalization of $198.60 billion, a PE ratio of 10.88, a P/E/G ratio of 4.03 and a beta of 0.76. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The firm’s 50-day moving average price is $46.96 and its 200 day moving average price is $45.12. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The company had revenue of $11.98 billion during the quarter. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.39 EPS for the current fiscal year.

Institutional Trading of Novo Nordisk A/S

Several large investors have recently bought and sold shares of NVO. Godfrey Financial Associates Inc. acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $25,000. Scarborough Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the first quarter valued at approximately $26,000. WealthCollab LLC increased its holdings in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares during the last quarter. Maseco LLP acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in Novo Nordisk A/S during the fourth quarter worth approximately $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.